# Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers

> **NCT02924155** · PHASE1 · COMPLETED · sponsor: **Samjin Pharmaceutical Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** SJP002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02924155
- **Lead sponsor:** Samjin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-05
- **Primary completion:** 2016-11-17
- **Final completion:** 2016-11-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02924155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02924155, "Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02924155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*